Lymphatic filariasis in India
Overview of lymphatic filariasis in India
Lymphatic filariasis in India is a significant public health issue caused by infection with the parasitic worms Wuchereria bancrofti, Brugia malayi, and Brugia timori. The disease is transmitted to humans through the bites of infected mosquitoes, primarily of the genera Culex, Anopheles, and Aedes. India bears a substantial burden of lymphatic filariasis, accounting for a large proportion of the global cases.
Epidemiology[edit | edit source]
India is one of the countries most affected by lymphatic filariasis, with millions of people at risk of infection. The disease is endemic in many states, particularly in the eastern, northeastern, and southern regions. The World Health Organization (WHO) has identified India as a priority country for the elimination of lymphatic filariasis.
Transmission[edit | edit source]
The transmission of lymphatic filariasis in India occurs primarily through the bite of infected mosquitoes. The larvae of the parasite enter the human body through the skin and migrate to the lymphatic system, where they mature into adult worms. These adult worms can live for several years, causing damage to the lymphatic system and leading to the characteristic symptoms of the disease.
Symptoms[edit | edit source]
Lymphatic filariasis can cause a range of symptoms, from mild to severe. The most common manifestations include lymphedema, elephantiasis, and hydrocele. Lymphedema is the swelling of the limbs, while elephantiasis refers to the thickening of the skin and underlying tissues. Hydrocele is the swelling of the scrotum in males. These symptoms can lead to significant disability and social stigma.
Prevention and Control[edit | edit source]
The Indian government, in collaboration with the WHO and other partners, has implemented several strategies to control and eliminate lymphatic filariasis. The primary approach is the Mass Drug Administration (MDA) program, which involves the annual distribution of antifilarial medications to at-risk populations. The goal is to interrupt the transmission of the disease by reducing the number of microfilariae in the blood of infected individuals.
Elimination Efforts[edit | edit source]
In 2018, the Indian government launched the Accelerated Plan for Elimination of Lymphatic Filariasis, aiming to eliminate the disease as a public health problem by 2020. This plan includes strengthening the MDA program, improving surveillance, and enhancing community awareness and participation. The program also focuses on providing care and support to those already affected by the disease.
Challenges[edit | edit source]
Despite significant progress, several challenges remain in the fight against lymphatic filariasis in India. These include logistical difficulties in reaching remote populations, ensuring high coverage and compliance with MDA, and addressing the social and economic impacts of the disease on affected individuals and communities.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD